"The assets acquired from the Dendreon deal are expected to account for 9% of the Growth segment’s revenues in 2016."
"Valeant’s Investment Here Could Improve Future Profit Margins"
The remaining bashers are all about spreading disinformation. I believe Dendreon's Assets are worth a Fortune.
It's very obvious that Dendreon's shareholders were cheated with those Asset deals. I think it will become even more clear in the future because BP's solutions will be heavily based on Dendreon's technology.
A $35 Billion market, and Valeant "paid" about $495 Million for all of Dendreon's Assets. It's truly Unbelievable.
"Unfortunately, Valeant's peers may not be particularly eager to pay market value for assets that might become available via a bankruptcy fire sale in the not-so-distant future. And as an ironic real world example, Valeant played this exact same game with the now-defunct cancer company Dendreon, acquiring its prostate cancer treatment Provenge for a meager two years' worth of the therapy's annual sales. That's a huge bargain for an FDA-approved cancer therapy, and it shows why Valeant may in fact struggle to consistently strike deals at reasonable prices.'
Yep, and they also managed to suppress most of the Provenge good news.